<DOC>
	<DOCNO>NCT01690533</DOCNO>
	<brief_summary>The objective study assess efficacy safety Avelox Tablet 400 mg ( hereinafter `` Avelox '' ) treat secondary infection chronic respiratory disease.It local prospective observational study patient receive Avelox tablet Laryngopharyngitis , Tonsillitis , Bronchitis acute , Pneumonia , Secondary infection chronic respiratory disease , Sinusitis . A total 500 patient enrol assessed period treatment Avelox .</brief_summary>
	<brief_title>Special Drug Use Investigation - Assessment Efficacy Safety Treating Secondary Infection Chronic Respiratory Disease</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients secondary infection chronic respiratory disease ( exclude acute bronchitis patient determine without chronic respiratory tract disease base medical history , xray finding , and/or finding ) meet follow criterion : 20 year old old infection mild moderate severity Patients meet follow criterion immediately start therapy : ≥37°C body temperature , expectoration purulent mucopurulent sputum , either white blood cell count ≥8,000/mm3 CRP ≥0.7 mg/dL Patients contraindicate base product label .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Avelox</keyword>
	<keyword>Laryngopharyngitis</keyword>
	<keyword>Tonsillitis</keyword>
	<keyword>Bronchitis acute</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Secondary infection chronic respiratory disease Sinusitis</keyword>
</DOC>